Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label, Randomized, Non-Comparative Clinical Trial of ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in Subjects With Recurrent Ovarian Cancers

NCT05601752 is registered in ClinicalTrials.gov with USWM CT, LLC as lead sponsor.

NCT NCT05601752
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05601752 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label, Randomized, Non-Comparative Clinical Trial of ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in Subjects With Recurrent Ovarian Cancers
Lead sponsor
USWM CT, LLC
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 26, 2023
Completion date
August 12, 2026
Enrollment
66 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer